European Association for the Study of Obesity May 12 2025 Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs form part of their treatment, new research being presented at year's European Congress on Obesity (ECO 2025) suggests. Glucagon -like peptide-1 (GLP-1) receptor agonists mimic the action of a hormone called GLP-1 to reduce appetite and feelings of hunger, slow the release of food from the stomach and